Navigation Links
Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
Date:3/12/2008

The Company has an ongoing Phase 1-2 trial that combines Genasense with Abraxane(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) (Abraxis BioScience, Inc.) plus Temodar(R) (temozolomide) Capsules (Schering-Plough Corporation) in patients with advanced melanoma. The new study represents the rapid clinical translation of preclinical results that showed marked anticancer synergy with this drug combination. The new study evaluates the safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination in chemotherapy- nave patients who have normal LDH levels. Updated results from this trial have been submitted to the 2008 annual meeting of the American Society of Clinical Oncology (ASCO).

Phase 3/Chronic Lymphocytic Leukemia (CLL)/NDA Status: In 2007, Genta appealed a prior "non-approvable" decision on the Genasense New Drug Application (NDA) for patients with relapsed/refractory CLL, and the appeal is now pending before the Director of FDA's Center for Drug Evaluation and Research (CDER). Extended follow-up during 2007 has indicated that patients who achieved complete remission (i.e., the study's primary endpoint) on the Genasense treatment arm have also enjoyed extended survival. Updated results from this trial have been submitted to the 2008 annual meeting of the American Society of Clinical Oncology (ASCO). The Company has met with FDA to discuss this appeal, and a decision from CDER is expected in the current calendar quarter.

High-Dose Intermittent Dose-Schedules: The Company has shown that high- dose, intermittent Genasense treatment was active and increased drug uptake in preclinical models of human lung cancer, colon cancer and melanoma. Moreover, twice-per-week Genasense dosing amplified the activity of multiple tyrosine kinase inhibitors, including erlotinib, imatinib, sunitinib and sorafenib, used either alone or in combination with a taxane.

Genta has now completed clinical trials to evaluate in
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
2. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
4. Genta Clinical Programs Featured at American Society of Hematology Meeting
5. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
6. Genta Incorporated Announces Third Quarter 2007 Financial Results
7. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
8. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
11. Inclinix Announces New Patent for Expert System Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  Today the U.S. Food and Drug Administration (FDA) ... of serogroup B meningococcal disease in individuals ... which received FDA approval in October, represent a significant ... "I have heard over and over from ...
(Date:1/23/2015)... , Jan. 23, 2015 A lot of discussion ... methods for treating  certain illnesses, injuries, or conditions. As medical ... previous treatment methods with ones that they consider to be ... there is not one textbook method of treatment that stands ...
(Date:1/23/2015)... DES MOINES, Iowa , Jan. 23, 2015  The Partnership to ... Iowa health care leaders and a new study ... prescription medications. The PFCD is a nationwide coalition working to educate ... The research released at the Capitol was focused on how the ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2No One-Size-Fits-All Remedy for Hernia Correction 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3
... ALISO VIEJO, Calif., May 1, 2012   Avanir Pharmaceuticals, Inc. ... for the quarter ended March 31, 2012 before market open ... conference call and an audio webcast at 9:00 am Eastern ... Conference Call Information: Domestic callers: 1 (866) 543-6411 ...
... today the addition of 8000 square feet to ... next to the company,s flagship showroom, will house ... launched lab equipment maintenance and repair department. ... In celebration of the expansion, and to show ...
Cached Medicine Technology:BioSurplus Expands, Debuts New 8000 Square Foot Warehouse and Service Facility 2
(Date:1/22/2015)... January 22, 2015 Four years since the release ... which coincided with the marriage of Avasa & Matthew Love – ... which is scheduled for release through White Swan Records on February ... there is a sacred path available to all of us to ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 EBSCO Information ... (AMA) are expanding their relationship in an effort to further ... the world. While EBSCO has long made AMA journals available ... sales agent for The JAMA Network. , Long ...
(Date:1/22/2015)... JJsHouse.com is a famous dress online store for wedding dresses ... latest collection of wedding dresses , and launches a site-wide ... wedding dress on your big day; the wedding gown is ... wants to find the most suitable wedding dress. Now, we ...
(Date:1/22/2015)... January 22, 2015 Lower-Auto-Insurance.com has released a new ... in a car for reducing the costs of an auto ... also be able to get lower prices for their vehicle insurance ... important role in determining policy costs. Because of this, drivers ...
(Date:1/22/2015)... Ga., USA (PRWEB) January 22, 2015 ... a statewide data management system with support from GEOSYSTEMS, ... , The new solution will leverage Hexagon Geospatial’s ... and vector data as well as point clouds and ...
Breaking Medicine News(10 mins):Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... 27 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc.,(NYSE: ... medical device,research and development outsourcing company with operations ... Hu, the Company,s Chief Operating,Officer, will present at ... December 3, 2008, at 12:00 pm Eastern Standard ...
... Oregon wineries auction special Pinot Noirs to benefit healthcare services for ... this cause for 17 years, producers preview outstanding 2007 vintage. ... ... Patrons of Salud! The Oregon Pinot Noir Auction contributed generously to ...
... patients will benefit, researchers say , , WEDNESDAY, Nov. 26 (HealthDay ... with a certain type of non-Hodgkin lymphoma have a better ... , Three different signatures of gene activity, or ... gene -- have been identified in people with diffuse large ...
... FORMAS, Sweden, has granted 5.9 million SEK to a ... and effects of the anti-viral drug Tamiflu on the ... all over the world for use in fighting the ... influenza viruses may develope resistance to this vital pharmaceutical, ...
... - Company alters strategy ... - Debt financing is secured as component ... 26 /PRNewswire-FirstCall/ - CRH Medical Corporation (CRM:TSX-V) announced today unaudited results for ... new strategy designed to mitigate the need to obtain financing from the ...
... Ky., Nov. 26 Almost Family, Inc.,(Nasdaq: ... Kentucky Certificate,of Need and home health license of the ... in Elizabethtown, KY. The,certificate will enable Almost Family ... of the metro Louisville area. , ...
Cached Medicine News:Health News:WuXi PharmaTech to Present at 20th Annual Piper Jaffray Healthcare Conference 2Health News:Despite Economy, Oregon Wine Benefit !Salud! Raises Over $735,000 2Health News:Despite Economy, Oregon Wine Benefit !Salud! Raises Over $735,000 3Health News:Genes May Predict Lymphoma Treatment Outcome 2Health News:Fate and effects of the drug Tamiflu in the environment 2Health News:CRH Medical reports Q3 2008 results 2Health News:CRH Medical reports Q3 2008 results 3Health News:CRH Medical reports Q3 2008 results 4Health News:CRH Medical reports Q3 2008 results 5Health News:CRH Medical reports Q3 2008 results 6Health News:Almost Family Announces Acquisition of Kentucky Home Health Certificate of Need 2Health News:Almost Family Announces Acquisition of Kentucky Home Health Certificate of Need 3
Rotating 360 degrees, 3 mm x 7 mm bite....
45 degree, forward 3 mm, 4 mm x 5 mm cup, length of shaft 140 mm, overall length 8.3 inches....
20 mm. Plastic, methylmethacrylate. Supplied sterile....
Small right. Teflon orbital plates....
Medicine Products: